Form 4: Y-mAbs Therapeutics Executive Thomas Gad Sells Shares
SEC Form 4 Filing
Thomas Gad, Chief Business Officer of Y-mAbs Therapeutics, sold a total of 95,000 shares of common stock in two transactions on September 13 and 16, 2024.
Summary
- Thomas Gad, the Chief Business Officer of Y-mAbs Therapeutics, Inc., reported the sale of company stock.
- On September 13, 2024, Gad sold 65,000 shares of common stock at a weighted average price of $13.47 per share.
- On September 16, 2024, Gad sold 30,000 shares of common stock at a weighted average price of $12.97 per share.
- Following these transactions, Gad directly owns 158,700 shares and indirectly owns 67,681 shares through GAD Enterprises LLC and 60,000 shares through his children.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of stock sales by an executive. The sales themselves don't necessarily indicate a positive or negative outlook for the company.
Industry Context
This filing is a routine disclosure of insider trading activity. It's common for executives to periodically sell shares for personal financial management.
Stakeholder Impact
- The stock sale could potentially create short-term selling pressure on the stock price, impacting shareholders.
Key Dates
| Date | Description |
|---|---|
| 09/13/2024 | Thomas Gad sold 65,000 shares of Y-mAbs Therapeutics stock. |
| 09/16/2024 | Thomas Gad sold 30,000 shares of Y-mAbs Therapeutics stock. |
| 09/17/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.